ArticleVaccines2020
CD8
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Unveiling the immune microenvironment in sinonasal intestinal type adenocarcinoma: new arguments for immunotherapy.Oncoimmunology · 2026Article
- Characterization of CD8 + and CD68 + Microenvironment and PDL1 Expression in HPV-related Multiphenotypic Sinonasal Carcinoma.Head and neck pathology · 2026Article
- Clinical, genetic and immunohistochemical characterization of sinonasal tumors with neuroectodermal differentiation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Rare Head and Neck Cancers and Pathological Diagnosis Challenges: A Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2024Review
- Low-dose nivolumab and cabozantinib in recurrent intestinal-type papillary adenocarcinoma of the sinonasal region.BMJ case reports · 2023Article
- Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma.International journal of molecular sciences · 2023Article
- Review
- The Prognostic Role of the Immune Microenvironment in Sinonasal Intestinal-Type Adenocarcinoma: A Computer-Assisted Image Analysis of CD3Journal of personalized medicine · 2023Article
- Article
- Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers.Journal of clinical medicine · 2022Review
- Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors.Biomedicines · 2022Article
- Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells.Cancer immunology, immunotherapy : CII · 2022Article
- Prognostic and Therapeutic Implications of Immune Classification by CD8International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIntestinal-type adenocarcinoma (ITAC) is a rare tumour occurring in the ethmoid sinus. Recent years have brought advances in endoscopic surgery and precision radiotherapy; however, five-year overall survival has not improved and remains at 35-80%, depending on tumour stage and histology. Therefore, there is a need for new therapeutic options.
methodsWe evaluated CD8
resultsThe presence of intratumoural CD8
conclusionsTMIT classification did not have additional prognostic value over CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.